Uncategorized
Ocugen to advance pipeline with $7.5 million in Series B financing
Ocugen has closed a $7.5 million round of Series B funding to support the advancement of potential sight-saving ophthalmology products into clinical trials, the company announced in a press release. Led by the Turkish pharmaceutical company Abdi Ibrahim and the JSC Lancaster Group from Kazakhstan, investors also included Frank Leo and John Zhang, PhD.